chrisvoncsefalvay/vaers-outcomes huggingface dataset:
No adverse event; the patient was administered one dose of MMR II inadvertently by the intramuscular route; the patient was administered one dose of MMR II inadvertently by the intramuscular route; This spontaneous report was received from a nurse referring to a patient of unknown age and gender. Patient's concurrent conditions, concomitant therapies, previous drug, reactions, allergies, historical drugs or medical history were not reported.      On an unknown date, the patient was vaccinated with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (rHA) (M-M-R II) subcutaneous injection, via intramuscular route, instead of the subcutaneous route (incorrect route of product administration); lot No. R031636 has been verified to be a valid lot number, expiration date reported as November 2020, but upon internal validation established as 01-NOV-2020 (strength, dose, frequency, anatomical location, and indication were not reported). No adverse event was reported.  The causality assessment between measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (rHA) (M-M-R II) administration and incorrect route of product administration occurrence was not provided by the reporter.
Patient vaccinated x2 (Moderna): 1/26/21, 3/30/21  Patient admitted to facility 1/31/22 after testing positive for COVID19
within 2 hours, i felt nauseous and queasy; I had eaten nothign to cause that.  Later in the day, I had itching all over my skin and even at my eyes,  inside my ears, my scalp and the bottom of my feet..  I took 35 mg dose of benedryl to help with the itching.  The benedryl helped and when I woke up this morning I still had some itching in my ears and eyes  but not too severe. I did not take more benedryl.
I had a fever, aches, chills, fatigue for approximately 24 hours. In addition, I had sharp pain (only when walking) in my right lower abdomen and in the second toe on my left foot.
1 hour post vax the pt developed pallor, lethargy, vomiting, urticaria. Was seen by a pediatrician and was already improving. Treated with oral antihistamine. The pt recovered completely within 24 hours.
vomiting; diarrhea; This spontaneous case was reported by a consumer and describes the occurrence of VOMITING (vomiting) and DIARRHOEA (diarrhea) in a 27-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Schizoaffective disorder. Concomitant products included LITHIUM, TRAZODONE and PALIPERIDONE (INVEGA [PALIPERIDONE]) for an unknown indication.   On 28-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 25-Feb-2021, the patient experienced VOMITING (vomiting) and DIARRHOEA (diarrhea). At the time of the report, VOMITING (vomiting) and DIARRHOEA (diarrhea) outcome was unknown.
MULTIPLE SUBSEGMENTAL PULMONARY EMBOLI WITHOUT ACUTE COR PULMONALE 4/4/2023 HEMATURIA ACUTE PULMONARY EMBOLISM 4/4/2023 HEMATURIA MULTIPLE SUBSEGMENTAL PULMONARY EMBOLI WITHOUT ACUTE COR PULMONALE 4/4/2023 MULTIPLE SUBSEGMENTAL PULMONARY EMBOLI WITHOUT ACUTE COR PULMONALE ACUTE PULMONARY EMBOLISM 4/4/2023 MULTIPLE SUBSEGMENTAL PULMONARY EMBOLI WITHOUT ACUTE COR PULMONALE
This spontaneous report was received from a pharmacist refers to a 69 year old female patient. On an unknown date the patient was vaccinated with ZOSTAVAX vial (dose, route, frequency and lot # unspecified). No concomitant medications were reported. On an unknown date the patient had some redness up her arm after receiving a dose of ZOSTAVAX on an unspecified date. There was no PQC involved. The outcome of the event was unknown. Causality assessment was not reported. Additional information is not expected. Consent to follow up was not provided.
Swelling in lymph nodes in same arm of injection; This spontaneous case was reported by a pharmacist and describes the occurrence of VACCINATION SITE LYMPHADENOPATHY (Swelling in lymph nodes in same arm of injection) in an 18-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 12-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE LYMPHADENOPATHY (Swelling in lymph nodes in same arm of injection). At the time of the report, VACCINATION SITE LYMPHADENOPATHY (Swelling in lymph nodes in same arm of injection) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment and concomitant medicines were not provided  Action taken with mRNA-1273 in response to the event was unknown
Started my period 7 days early (had never happened in my life).  It was thick and dark brown and black.  Then when the period was supposed to start, I had a normal, long (heavy) red period as if I hadn?t already been bleeding got a week.  I?ve been tracking my cycles for over a decade. This is totally unusual.
Diagnosed with prolonged amenorrhea. Has had one period on her own.  Patient is 22 yrs old.
Arthralgias in PIPs 3-5 of feet shortly after 3rd Anthrax vaccination
101.5 temperature, extreme fatigue, extensive muscle aches, headache, chills, heart rate elevated, skipping beats and then unexplained tachycardia when at rest this lasted until the first week of June 2021  They in August, I started getting warnings on my watch that I was having tachycardia 120 bpm
Fever and Chills, severe dizziness, headache, appetite loss.  Resolved by 8:00 p.m.
Possible Shingles rash on right anterolator/posteior shoulder. Erythema, with multiple small pustules present. Patient states rash as more painful than itchy.
change in mensural cycle. early onset of period followed by another period after 14 days characterized by longer length then usual.
VOMITING; FLU LIKE SYMPTOMS; NAUSEA; This spontaneous report received from a patient concerned a patient of unspecified age and sex. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unk) dose was not reported, administered on 08-MAR-2021 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On 14-MAR-2021, the subject experienced vomiting. On 14-MAR-2021, the subject experienced flu like symptoms. On 14-MAR-2021, the subject experienced nausea. On 15-MAR-2021, Laboratory data included: COVID-19 virus test (NR: not provided) Negative. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from vomiting, and nausea on MAR-2021, and had not recovered from flu like symptoms. This report was non-serious.
Pt was given Typhoid (left deltoid) and Hep A (rt deltoid) on 03/30/15. He had a growing rash that developed first on his rt deltoid on 04/13/15 and was seen in a local urgent care a few days later after OTC Benadryl and steroid cream weren't working. He received steroids that are helping. He had previously never had either vaccine.
This spontaneous report was received from a physician refers to a patient of unknown age and gender. On 31-AUG-2015, the patient was vaccinated with improperly stored PROQUAD (Merck) lot # K025766, expiry date 08-JUN-2015. This is one of the several reports received from the same reporter. Additional information has been requested.
tested positive for COVID with mild symptoms and low fever; tested positive for COVID with mild symptoms and low fever; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  An 11-year-old female patient (not pregnant) received BNT162b2 (COMIRNATY), on 10Nov2021 as dose 1, single (Lot number: FK5127), in right arm and on 01Dec2021 as dose 2, single (Lot number: FK5618) at the age of 11 years, in right arm for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 09Jan2022, outcome "recovered" and all described as "tested positive for COVID with mild symptoms and low fever". The patient underwent the following laboratory tests and procedures: Body temperature: (09Jan2022) low; SARS-CoV-2 test: (11Jan2022) Positive, notes: Nasal Swab. Therapeutic measures were not taken as a result of vaccination failure, covid-19.  No follow-up attempts are possible. No further information is expected.
Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 035C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 27-Oct-2021 at 3:47 PM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. In 2021, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). On 27-Oct-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Age of patient was reported as 68.24 for dose administered on 27-Oct-2021. No concomitant medications were reported. Batch number 035C21A underwent temperature excursion on 27-Oct-2021. 2 vials with temperature 29 degrees Fahrenheit at 09:00 AM which were moved to fridge on 29-Sept-2021 and beyond used date was 29-Oct-2021. 4 vials with temperature 32 degrees Fahrenheit at 10:00 AM which were moved to fridge on 05-Oct-2021 and beyond used date was 04-Nov-2021. Product moved to clinic on 27-Oct-2021. Vial was in cooler storage and was not in frozen storage during high-pace COVID-19 vaccination at around 2021. Vials were only punctured right before administration. Vaccines were not frozen at time of administration. It was reported that each time a vial was put into a cooler, sometimes there was a period of 1 hour or 1 hour and a half approximately, when temperature data logger registered a temperature of 34- or 35-degree Fahrenheit. Temperature recordings were taken using a Fisher brand traceable temperature monitor at every hour. No treatment medications were reported.   This case was linked to MOD-2022-566976 (Patient Link).
12/18/2020 Day after injection chestpain that was progessive day before visit to ER on 12/19/2020.Described pain as pressure in middle of chest, radiated to upper left chest under armpit, with associated nausea, feelings of Heart Palpitations, EKG shows 98bpm, normal intervals, t wave inversion lead III, normal sinus rhythm. BP 151/83, sats 100% temp 98.4 HR 99.  labs cardiac enzymes negative, Ddimer elevated,CT chest negative for pulm embolism and chest xray no acute process. scheduled to see her PCP on 12/22. diagnosed with lymphadenopathy and chest pain,  the lymph nodes noted after injection of covid #1 vaccine.  12/22/2020 was given a steroid shot in the PCP office,
Information has been rec'd from a RN from the hlth dept concerning several weird cases where people who in approximately 1968 were vaccinated with mono valent measles vaccine are presently exhibiting measles - type symptoms. The nsg stated that she felt this was not measles, but something else. Unspecified medical attention was sought. Follow up information from the nsg indicated that one individual rec'd a mono valent measles vaccine Manufacturer unknown (lot # 6142221330B) in approximately 1968. It was noted that lot # 6142221330B corresponds with rubella virus vaccine live (meruvax II) that was released for sale on Nov 6,1995 and expired Sept 5, 97. She reported that she was not sure of the date of vaccination and could not explain how the pt got a vaccine in 1968 that was not released until 1995. She stated that the pt developed a rash on approximately mar 26, 2001 that tested negative for measles. The reporter felt that the rash had to be caused by something else and it was not a vaccine reaction. She noted that blood specimens were sent to the CDC for testing and she had not rec'd any results from these test. It was also reported that there were 15 confirmed cases of measles (WAES #01111103) and numerous other rash illnesses that proved not to be measles (WAES #01111104). She was not able to elaborate on these cases. Additional information has been requested.
No additional AE; HCP states that ROTATEQ vaccine that underwent a supported temperature excursion on Dec 26, 2022 was administered to a patient on Dec 27, 2022.; This spontaneous report has been received from a nurse, referring a patient of unknown age and gender. The patient's medical history, concurrent conditions, and concomitant medications were not provided.  On 27-DEC-2022, the patient was vaccinated with an improperly stored dose of rotavirus vaccine, live, oral, pentavalent (ROTATEQ) oral liquid (lot number 1837127 has been verified to be a valid lot number, expiry date 14-OCT-2023) (strength, dose, and frequency were not reported) indicated as prophylaxis (product storage error).  The rotavirus vaccine, live, oral, pentavalent (ROTATEQ) vaccine was stored at a temperature of 15.4 °C for a time frame of 8 hours. The re was no previous temperature excursion.  No additional adverse event were reported.
My daughter took the covid vaccine. Her second dose was on June 2.2021. She was diagnosed with long QT syndrome on July 27, 2031. Could this be have caused by the Pfizer vaccine. This is what she took. She had couple of fainting episodes. She was diagnosed at hospital. We want to make sure the vaccine did. It cause this. Is there a correlation between that two things. The heart containing cause by the covid vaccine cause long qt syndrome.
Pretty unconfortable after effects/Possible the worst of any vax I've ever gotten; Body aches/Burning pain; Electric feeling type of pain; Injection site was tender; Injection site was swollen; Injection site was eventually itchy; Lethargy; No appetite; Felt crappy; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of injection site tenderness in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   The patient's past medical history included shingles (had shingles many years ago).   On an unknown date, the patient received Shingles vaccine. On an unknown date, an unknown time after receiving Shingles vaccine, the patient experienced injection site tenderness (Verbatim: Injection site was tender), injection site swelling (Verbatim: Injection site was swollen), injection site itching (Verbatim: Injection site was eventually itchy), discomfort (Verbatim: Pretty unconfortable after effects/Possible the worst of any vax I've ever gotten), pain (Verbatim: Body aches/Burning pain), lethargy (Verbatim: Lethargy), appetite absent (Verbatim: No appetite), feeling bad (Verbatim: Felt crappy) and neuropathic pain (Verbatim: Electric feeling type of pain). The outcome of the injection site tenderness, injection site swelling, injection site itching, lethargy, appetite absent and feeling bad were resolved (duration 3 days) and the outcome of the discomfort was not reported and the outcome of the pain and neuropathic pain were resolved.   It was unknown if the reporter considered the injection site tenderness, injection site swelling, injection site itching, discomfort, pain, lethargy, appetite absent, feeling bad and neuropathic pain to be related to Shingles vaccine.   It was unknown if the company considered the injection site tenderness, injection site swelling, injection site itching, discomfort, pain, lethargy, appetite absent, feeling bad and neuropathic pain to be related to Shingles vaccine.   Additional Information: GSK Receipt Date: 15-MAR-2023 This case was reported by a patient via interactive digital media. The shingles vaccine had pretty uncomfortable after effects. The reporter stated that possibly the worst of any vaccine he/she had ever gotten. The patient experienced body aches, lethargy, no appetite, felt crappy and his/her injection site was tender, swollen and eventually itchy too for nearly 3 days. All that being said it was a piece of a cake compared to the horrid and long lasting pain and rash associated with shingles. The reporter further stated that you could still get the shingles vaccine if you had shingles before by the way and the shingles would consume you.  The patient further stated that it was hard to describe burning and electric feeling type of pain that was nearly unbearable when anything touched it for weeks. The follow up would not possible as no contact details were available.
This is a spontaneous report received from a contactable consumer. A female patient received the 1st dose of BNT162B2 (Pfizer-BioNTech COVID-19 vaccine, batch/lot# unknown), on Mar 29, 2021, single dose, for COVID-19 immunisation. The patient's medical history and concomitant medications not reported. The patient had pain in extremity/pain in her arm that went up into her neck, neck pain, malaise/doesn't feel well and influenza-like illness/flu like symptoms; all onset Mar 2021, with outcome of unknown. Additional information: Event took place after the vaccination. No follow-up attempts possible. Information about batch/lot number cannot be obtained. No further information  expected.
No adverse event; 2 children received the adult version of the Spikevax 2023-2024 prefilled syringe; This spontaneous case was reported by a pharmacist and describes the occurrence of WRONG PRODUCT ADMINISTERED (2 children received the adult version of the Spikevax 2023-2024 prefilled syringe) and NO ADVERSE EVENT (No adverse event) in a child patient of an unknown gender who received mRNA-1273.815 (SPIKEVAX 2023-2024 PFS) (batch no. 3030355) for COVID-19 prophylaxis.     No Medical History information was reported.    On 03-Oct-2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024 PFS) (unknown route) .5 milliliter. On 03-Oct-2023,  after starting mRNA-1273.815 (SPIKEVAX 2023-2024 PFS), the patient experienced WRONG PRODUCT ADMINISTERED (2 children received the adult version of the Spikevax 2023-2024 prefilled syringe). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, WRONG PRODUCT ADMINISTERED (2 children received the adult version of the Spikevax 2023-2024 prefilled syringe) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273.815 (SPIKEVAX 2023-2024 PFS) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for WRONG PRODUCT ADMINISTERED (2 children received the adult version of the Spikevax 2023-2024 prefilled syringe).    No concomitant medications were reported. No treatment medications were provided.   This case was linked to US-MODERNATX, INC.-MOD-2023-743700.; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-743700:1st Child case
cut her head; Patients second dose greater than 3 weeks due to fall; This is a spontaneous report from a contactable consumer or other non-Health Care Professional. A 81-years-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot number and Expiry date: Unknown), dose 1 via an unspecified route of administration on 27Mar2021 as DOSE 1, SINGLE for covid-19 immunization. Medical history included ongoing gastroesophageal reflux disease Verbatim: acid relux , ongoing hypertension Verbatim: high blood pressure , ongoing anxiety Verbatim: Anxiety. The patient received tetanus, a week after she fell, not given at hospital went to doctor 4-5 days later she gave her a tetanus shot vaccines within 4 weeks prior to the Covid vaccine. The patient received other medications of vaccination. The patient was not diagnosed with Covid 19 and has not been tested for Covid-19 Since the vaccination. Concomitant medication(s) included omeprazole (OMEPRAZOLE) taken for gastroesophageal reflux disease, start and stop date were not reported.On 17Apr2021 the patient experienced patient fell trying to get to second vaccine, cut her head, patients second dose greater than 3 weeks due. The outcome of event was unknown.  No follow-up attempts are needed. Information about lot/batch number cannot be obtained.  Amendment: This follow-up report is being submitted to amend previously reported information: To delete the event Missed dose.
She has had some redness around the injection site since then when she got up today she had a little bit of rash on her arm and some on her upper chest area.  As the day progressed it got worse.  It is on both of her legs, her buttocks, her trunk, and her arms
Left arm went sort of numb with pins and needle feeling 2 hours after administration and last for 1 full day. Raised red area that is 4 in x 4 in.
Clt. received Dtap IPV on 2-6-06. Reported swelling and redness 2-8-03, able to move left arm, no fever. Advised to come in to clinic for evaluation. Redness, swelling from shoulder to elbow, hot to touch, redness on outer aspect of arm, only. Advised to use cold compresses and give Benadryl and call back in AM. Called on 2-9-06, no improvement referred to PMD. PMD gave triamcinolone ointment. On 2-10-06 reported swelling and redness almost gone. No other complaints.
Body aches, headaches, suspected fever, vomiting 17 1/2 hours injection
Pt got shots 12/9/03 and on 12/11/03 pt developed right lower hip with urticarial lesions (erythema multiforme). Shot site had no rash and tenderness or swelling, there was no SOB.